$PRE_HEADER$           Developed under the direction and sponsorship of Novartis Pharmaceuticals Corporation.             For nearly 20 years, few large clinical trials have been solely dedicated to premenopausal women with metastatic breast cancer*           28 studies for POSTMENOPAUSAL women with mBC     2 dedicated studies for PREMENOPAUSAL women with mBC           *Large clinical trials were defined as Phase III trials of 200 or more women. Dated April 2018.           "We really need more data which is dedicated and applicable to our premenopausal women with metastatic disease." —Dr Nikita Shah         Hear from leading breast cancer experts and learn more           Dedicated to building a high standard of evidence specific to young women living with metastatic breast cancer           mBC=metastatic breast cancer.           Reference: ClinicalTrials.g‍ov. Search results for premenopausal metastatic breast cancer studies recruiting; not yet recruiting; active, not recruiting, completed, enrolling by invitation, suspended, terminated, withdrawn, unknown status; phase 3. Search results for postmenopausal metastatic breast cancer studies recruiting; not yet recruiting; active, not recruiting, completed, enrolling by invitation, suspended, terminated, withdrawn, unknown status; interventional studies; studies with female participants; phase 3. Accessed April 2, 2018.           This is a sponsored message from DMD on behalf of Novartis Pharmaceuticals Corporation. DMD provides sponsored health care-related messages from trusted third parties. This material is intended specifically and exclusively for US health care professionals. You are receiving this e-mail because you have subscribed and agreed to receive information from a DMD e-mail list.           If you prefer not to receive further messages from this sender, please click here and confirm your request.           DMD           102‌55 W. Higgins Ro‌ad, Suit‌e 280           Rosemont, IL 60‌018           DMD Privacy Policy                   Novartis Pharmaceuticals Corporation         © 20‍18 Novartis 4‌/‌18 BST-1181487